Catalyst Biosciences, Inc. (CBIO)
(Delayed Data from NSDQ)
$8.46 USD
+0.26 (3.17%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.45 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.46 USD
+0.26 (3.17%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.45 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Merck (MRK) Gets FDA Fast Track Tag for Anticoagulant Therapy
by Zacks Equity Research
A phase II study is ongoing on Merck's (MRK) MK-2060 in people with end-stage renal disease receiving hemodialysis.
Has Adicet Bio (ACET) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Adicet Bio, Inc. (ACET) and Catalyst Biosciences, Inc. (CBIO) have performed compared to their sector so far this year.
Has Catalyst Biosciences (CBIO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Catalyst Biosciences, Inc. (CBIO) and Humana (HUM) have performed compared to their sector so far this year.
Catalyst Biosciences, Inc. (CBIO) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Catalyst Biosciences, Inc. (CBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Catalyst Biosciences, Inc. (CBIO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Catalyst Biosciences, Inc. (CBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalyst Biosciences, Inc. (CBIO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Catalyst Biosciences, Inc. (CBIO) delivered earnings and revenue surprises of 5.88% and 13.20%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Biosciences, Inc. (CBIO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Catalyst Biosciences, Inc. (CBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cigna (CI) to Post Q1 Earnings: Will It Deliver a Beat?
by Zacks Equity Research
Cigna (CI) Q1 results are likely to reflect better revenues but a weak bottom line.
Is a Surprise Coming for Catalyst Biosciences (CBIO) This Earnings Season?
by Zacks Equity Research
Catalyst Biosciences (CBIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Catalyst Biosciences, Inc. (CBIO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Catalyst Biosciences, Inc. (CBIO) delivered earnings and revenue surprises of -2.60% and 46.70%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Select Medical (SEM) Earnings in Q1?
by Zacks Equity Research
Select Medical (SEM) Q1 results are likely to reflect improvement in patient volumes.
Insmed (INSM) Starts Dosing in Phase III Bronchiectasis Study
by Zacks Equity Research
Insmed (INSM) doses the first patient in the phase III ASPEN study evaluating its pipeline candidate brensocatib for the treatment of patients with bronchiectasis.
Blueprint Medicines' (BPMC) Gavreto Approved for Thyroid Cancer
by Zacks Equity Research
The FDA grants accelerated nod to Blueprint Medicines' (BPMC) Gavreto for treating patients with advanced/metastatic RET-altered thyroid cancer.
Vertex (VRTX) Symkevi/Kalydeco Label Expansion Gets EU Nod
by Zacks Equity Research
Vertex (VRTX) gets European approval for label expansion of Symkevi and Kalydeco combination pill in cystic fibrosis patients aged six to 11.
Biogen (BIIB) & Sage Therapeutics Partner for Depression Therapies
by Zacks Equity Research
Biogen (BIIB) and Sage Therapeutics (SAGE) collaborate to develop latter's zuranolone for depression indications and SAGE-324 for essential tremor.
Zacks.com featured highlights include: ODP, Myers, Catalyst, Vicor and Bally's
by Zacks Equity Research
Zacks.com featured highlights include: ODP, Myers, Catalyst, Vicor and Bally's
5 Stocks to Keep an Eye on as Analysts Initiate Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might led to solid price appreciation for stocks like ODP (ODP), Myers (MYE), Catalyst Biosciences (CBIO), Vicor (VICR) and Bally's (BALY).
Zacks.com featured highlights include: Catalyst Biosciences, UFP Industries, VeriSign, InMode and Castle Biosciences
by Zacks Equity Research
Zacks.com featured highlights include: Catalyst Biosciences, UFP Industries, VeriSign, InMode and Castle Biosciences
5 Stocks Set to Pop on New Analyst Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Catalyst Biosciences (CBIO), UFP Industries (UFPI), VeriSign (VRSN), InMode (INMD) and Castle Biosciences (CSTL).
Top Ranked Momentum Stocks to Buy for April 21st
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 21st
Catalyst Biosciences Enters Oversold Territory
by Zacks Equity Research
Catalyst Biosciences has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Company News For Dec 20, 2019
by Zacks Equity Research
Companies In The News Are: CAG, CBIO, MLHR, DRI
Company News For Oct 4, 2019
by Zacks Equity Research
Companies in the news are: STZ, BBBY, PEP, CBIO
Catalyst Biosciences Enters Oversold Territory
by Zacks Equity Research
Catalyst Biosciences, Inc. (CBIO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Zacks.com featured expert Kevin Matras highlights: Net Lease, K12, Brookline Bancorp, Catalyst Biosciences and Knoll
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Net Lease, K12, Brookline Bancorp, Catalyst Biosciences and Knoll